242 related articles for article (PubMed ID: 18645927)
1. Hypercoagulability and tissue factor gene upregulation in hematologic malignancies.
Falanga A; Barbui T; Rickles FR
Semin Thromb Hemost; 2008 Mar; 34(2):204-10. PubMed ID: 18645927
[TBL] [Abstract][Full Text] [Related]
2. Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils.
Falanga A; Marchetti M; Barbui T; Smith CW
Semin Hematol; 2005 Oct; 42(4):239-47. PubMed ID: 16210037
[TBL] [Abstract][Full Text] [Related]
3. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
[TBL] [Abstract][Full Text] [Related]
4. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; Neumann HA; van Vliet HH
Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
[TBL] [Abstract][Full Text] [Related]
5. Leukocytosis, JAK2V617F mutation, and hemostasis in myeloproliferative disorders.
Marchetti M; Falanga A
Pathophysiol Haemost Thromb; 2008; 36(3-4):148-59. PubMed ID: 19176988
[TBL] [Abstract][Full Text] [Related]
6. Genetic determinants of cancer coagulopathy, angiogenesis and disease progression.
Rak J; Klement P; Yu J
Vnitr Lek; 2006 Mar; 52 Suppl 1():135-8. PubMed ID: 16637463
[TBL] [Abstract][Full Text] [Related]
7. Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms.
Duchemin J; Ugo V; Ianotto JC; Lecucq L; Mercier B; Abgrall JF
Thromb Res; 2010 Sep; 126(3):238-42. PubMed ID: 20656333
[TBL] [Abstract][Full Text] [Related]
8. Blood cells diseases and thrombosis.
Leone G; Sica S; Chiusolo P; Teofili L; De Stefano V
Haematologica; 2001 Dec; 86(12):1236-44. PubMed ID: 11726314
[TBL] [Abstract][Full Text] [Related]
9. Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients.
Spanoudakis E; Bazdiara I; Kotsianidis I; Margaritis D; Goutzouvelidis A; Christoforidou A; Tsatalas C; Bourikas G
Ann Hematol; 2009 Jul; 88(7):629-32. PubMed ID: 19096846
[TBL] [Abstract][Full Text] [Related]
10. Intravascular clotting activation and bleeding in patients with hematologic malignancies.
Tallman MS; Kwaan HC
Rev Clin Exp Hematol; 2004 Jun; 8(1):E1. PubMed ID: 16029967
[TBL] [Abstract][Full Text] [Related]
11. Pathogenesis and management of bleeding in essential thrombocythemia and polycythemia vera.
Elliott MA; Tefferi A
Curr Hematol Rep; 2004 Sep; 3(5):344-51. PubMed ID: 15341701
[TBL] [Abstract][Full Text] [Related]
12. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
Vannucchi AM; Masala G; Antonioli E; Chiara Susini M; Guglielmelli P; Pieri L; Maggi L; Caini S; Palli D; Bogani C; Ponziani V; Pancrazzi A; Annunziato F; Bosi A
Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2068-73. PubMed ID: 19531676
[TBL] [Abstract][Full Text] [Related]
13. Hypercoagulability in patients with haematological neoplasia: no apparent initiation by tissue factor.
Negaard HF; Iversen PO; Østenstad B; Iversen N; Holme PA; Sandset PM
Thromb Haemost; 2008 Jun; 99(6):1040-8. PubMed ID: 18521506
[TBL] [Abstract][Full Text] [Related]
14. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention.
Landolfi R; Cipriani MC; Novarese L
Best Pract Res Clin Haematol; 2006; 19(3):617-33. PubMed ID: 16781491
[TBL] [Abstract][Full Text] [Related]
15. Thrombotic complications in essential thrombocythemia (ET): clinical facts and biochemical riddles.
Petrides PE; Siegel F
Blood Cells Mol Dis; 2006; 36(3):379-84. PubMed ID: 16563815
[TBL] [Abstract][Full Text] [Related]
16. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk.
Barbui T; Finazzi G
Semin Thromb Hemost; 2007 Jun; 33(4):321-9. PubMed ID: 17525889
[TBL] [Abstract][Full Text] [Related]
17. Arterial stenosis and atherothrombotic events in polycythemia vera and essential thrombocythemia.
Cucuianu A; Stoia M; Farcaş A; Dima D; Zdrenghea M; Paţiu M; Olinic D; Petrov L
Rom J Intern Med; 2006; 44(4):397-406. PubMed ID: 18386616
[TBL] [Abstract][Full Text] [Related]
18. [Vascular complications of essential thrombocythemia].
Bellucci S
Bull Acad Natl Med; 2007 Mar; 191(3):519-30; discussion 530-3. PubMed ID: 18072651
[TBL] [Abstract][Full Text] [Related]
19. Tissue factor and cancer.
Milsom C; Rak J
Pathophysiol Haemost Thromb; 2008; 36(3-4):160-76. PubMed ID: 19176989
[TBL] [Abstract][Full Text] [Related]
20. Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated hematological cancer. Time to change our therapeutic attitude with early upfront treatment?
Hasselbalch HC
Leuk Res; 2009 Jan; 33(1):11-8. PubMed ID: 18632152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
